Efficacy of ebastine for treatment of pruritic skin disease

Patient assessment with a self-administered questionnaire

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The efficacy of ebastine (Ebastel®), a second-generation antihistamine, for the treatment of pruritic skin disease was assessed by performing a questionnaire survey. Twenty-four patients who had atopic dermatitis and primarily presented with pruritus were treated with ebastine (10 mg once daily) for 4 weeks. Before and after the 4-week treatment period, the patients were asked to assess their pruritic symptoms by using a self-administered questionnaire. The questionnaire covered various aspects and the questions were randomly sorted to minimize interactions that could potentially bias the answers to successive questions. Four weeks of treatment with ebastine significantly reduced the frequency, severity, and intensity (VAS score) of pruritus, confirming that this drug effectively suppresses pruritus. Ebastine treatment also significantly relieved nocturnal pruritus that had caused sleep disturbance and thus improved daily activities, resulting in overall improvement of the patients' quality of life that had been impaired by pruritus. Compared with the response to prior treatment, the antipruritic effect of ebastine appeared more rapidly and persisted for a comparable duration after each dose. These results indicate that ebastine has a rapid and durable antipruritic effect, while causing fewer adverse events such as drowsiness, suggesting that this second-generation antihistamine may be a more satisfactory antipruritic agent for patients.

Original languageEnglish
Pages (from-to)321-327
Number of pages7
JournalNishinihon Journal of Dermatology
Volume71
Issue number3
DOIs
Publication statusPublished - Jun 1 2009

Fingerprint

Skin Diseases
Pruritus
Antipruritics
Non-Sedating Histamine H1 Antagonists
Therapeutics
Sleep Stages
Atopic Dermatitis
Surveys and Questionnaires
ebastine
Sleep
Quality of Life
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

@article{997e85b44ee04362b711aa376c5b7048,
title = "Efficacy of ebastine for treatment of pruritic skin disease: Patient assessment with a self-administered questionnaire",
abstract = "The efficacy of ebastine (Ebastel{\circledR}), a second-generation antihistamine, for the treatment of pruritic skin disease was assessed by performing a questionnaire survey. Twenty-four patients who had atopic dermatitis and primarily presented with pruritus were treated with ebastine (10 mg once daily) for 4 weeks. Before and after the 4-week treatment period, the patients were asked to assess their pruritic symptoms by using a self-administered questionnaire. The questionnaire covered various aspects and the questions were randomly sorted to minimize interactions that could potentially bias the answers to successive questions. Four weeks of treatment with ebastine significantly reduced the frequency, severity, and intensity (VAS score) of pruritus, confirming that this drug effectively suppresses pruritus. Ebastine treatment also significantly relieved nocturnal pruritus that had caused sleep disturbance and thus improved daily activities, resulting in overall improvement of the patients' quality of life that had been impaired by pruritus. Compared with the response to prior treatment, the antipruritic effect of ebastine appeared more rapidly and persisted for a comparable duration after each dose. These results indicate that ebastine has a rapid and durable antipruritic effect, while causing fewer adverse events such as drowsiness, suggesting that this second-generation antihistamine may be a more satisfactory antipruritic agent for patients.",
author = "Masutaka Furue",
year = "2009",
month = "6",
day = "1",
doi = "10.2336/nishinihonhifu.71.321",
language = "English",
volume = "71",
pages = "321--327",
journal = "Nishinihon Journal of Dermatology",
issn = "0386-9784",
publisher = "Kyushu University, Faculty of Science",
number = "3",

}

TY - JOUR

T1 - Efficacy of ebastine for treatment of pruritic skin disease

T2 - Patient assessment with a self-administered questionnaire

AU - Furue, Masutaka

PY - 2009/6/1

Y1 - 2009/6/1

N2 - The efficacy of ebastine (Ebastel®), a second-generation antihistamine, for the treatment of pruritic skin disease was assessed by performing a questionnaire survey. Twenty-four patients who had atopic dermatitis and primarily presented with pruritus were treated with ebastine (10 mg once daily) for 4 weeks. Before and after the 4-week treatment period, the patients were asked to assess their pruritic symptoms by using a self-administered questionnaire. The questionnaire covered various aspects and the questions were randomly sorted to minimize interactions that could potentially bias the answers to successive questions. Four weeks of treatment with ebastine significantly reduced the frequency, severity, and intensity (VAS score) of pruritus, confirming that this drug effectively suppresses pruritus. Ebastine treatment also significantly relieved nocturnal pruritus that had caused sleep disturbance and thus improved daily activities, resulting in overall improvement of the patients' quality of life that had been impaired by pruritus. Compared with the response to prior treatment, the antipruritic effect of ebastine appeared more rapidly and persisted for a comparable duration after each dose. These results indicate that ebastine has a rapid and durable antipruritic effect, while causing fewer adverse events such as drowsiness, suggesting that this second-generation antihistamine may be a more satisfactory antipruritic agent for patients.

AB - The efficacy of ebastine (Ebastel®), a second-generation antihistamine, for the treatment of pruritic skin disease was assessed by performing a questionnaire survey. Twenty-four patients who had atopic dermatitis and primarily presented with pruritus were treated with ebastine (10 mg once daily) for 4 weeks. Before and after the 4-week treatment period, the patients were asked to assess their pruritic symptoms by using a self-administered questionnaire. The questionnaire covered various aspects and the questions were randomly sorted to minimize interactions that could potentially bias the answers to successive questions. Four weeks of treatment with ebastine significantly reduced the frequency, severity, and intensity (VAS score) of pruritus, confirming that this drug effectively suppresses pruritus. Ebastine treatment also significantly relieved nocturnal pruritus that had caused sleep disturbance and thus improved daily activities, resulting in overall improvement of the patients' quality of life that had been impaired by pruritus. Compared with the response to prior treatment, the antipruritic effect of ebastine appeared more rapidly and persisted for a comparable duration after each dose. These results indicate that ebastine has a rapid and durable antipruritic effect, while causing fewer adverse events such as drowsiness, suggesting that this second-generation antihistamine may be a more satisfactory antipruritic agent for patients.

UR - http://www.scopus.com/inward/record.url?scp=67849092051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67849092051&partnerID=8YFLogxK

U2 - 10.2336/nishinihonhifu.71.321

DO - 10.2336/nishinihonhifu.71.321

M3 - Article

VL - 71

SP - 321

EP - 327

JO - Nishinihon Journal of Dermatology

JF - Nishinihon Journal of Dermatology

SN - 0386-9784

IS - 3

ER -